12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Company News  |  Deals

SuppreMol, Bayerische Patentallianz GmbH deal

SuppreMol licensed exclusive, worldwide rights from the University Hospital of Regensburg to preclinical compound SM401, a humanized mAb against IL-3 in preclinical development to diagnose...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >